IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$38.45+1.09 (+2.92%)
Close on Nov 17, 2026Market cap $39.11MP/E –Yield –
IRulya Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
No price to sales ratio figures for IRulya Therapeutics
IRulya Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?